Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOME study: Montelukast dose finding in erosive osteoarthritis of the hands
2023-506137-30-00Phase 2Completed
- Sponsor
- Farmalíder
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of montelukast in erosive hand osteoarthritis (EHOA) (5 arms), sponsored by Farmalíder. Primary endpoint: Pain intensity difference (PID) at 8 weeks. Started Nov 2023; status: completed.
02
Drugs
montelukast
03
Conditions
erosive hand osteoarthritis (EHOA)
Beyond the preview
Go deeper on 2023-506137-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506137-30-00.